GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » Cyclically Adjusted Revenue per Share

Harbin Medisan Pharmaceutical Co (SZSE:002900) Cyclically Adjusted Revenue per Share : ¥4.61 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Harbin Medisan Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2025 was ¥0.640. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.61 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-19), Harbin Medisan Pharmaceutical Co's current stock price is ¥14.33. Harbin Medisan Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ¥4.61. Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 3.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harbin Medisan Pharmaceutical Co was 3.10. The lowest was 2.37. And the median was 2.51.


Harbin Medisan Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 4.61

Competitive Comparison of Harbin Medisan Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


;
;

Harbin Medisan Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Harbin Medisan Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.64/115.1156*115.1156
=0.640

Current CPI (Mar. 2025) = 115.1156.

Harbin Medisan Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 95.237 0.000
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201503 0.709 99.900 0.817
201512 0.000 100.600 0.000
201609 0.765 102.400 0.860
201612 0.961 102.600 1.078
201703 0.737 103.200 0.822
201706 0.860 103.100 0.960
201709 1.209 104.100 1.337
201712 1.567 104.500 1.726
201803 2.207 105.300 2.413
201806 1.264 104.900 1.387
201809 1.711 106.600 1.848
201812 1.925 106.500 2.081
201903 1.590 107.700 1.699
201906 1.972 107.700 2.108
201909 1.643 109.800 1.723
201912 1.564 111.200 1.619
202003 0.903 112.300 0.926
202006 1.110 110.400 1.157
202009 1.140 111.700 1.175
202012 1.053 111.500 1.087
202103 0.727 112.662 0.743
202106 0.802 111.769 0.826
202109 0.754 112.215 0.773
202112 0.764 113.108 0.778
202203 0.811 114.335 0.817
202206 0.847 114.558 0.851
202209 0.783 115.339 0.781
202212 0.907 115.116 0.907
202303 1.136 115.116 1.136
202306 0.944 114.558 0.949
202309 0.851 115.339 0.849
202312 0.949 114.781 0.952
202403 0.788 115.227 0.787
202406 0.805 114.781 0.807
202409 1.126 115.785 1.119
202412 0.984 114.893 0.986
202503 0.640 115.116 0.640

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Harbin Medisan Pharmaceutical Co  (SZSE:002900) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Harbin Medisan Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.33/4.61
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harbin Medisan Pharmaceutical Co was 3.10. The lowest was 2.37. And the median was 2.51.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Harbin Medisan Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Medisan Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co Headlines

No Headlines